Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 00:00 | 2026-03-23 | CYRX | Cryoport, Inc. | Sawicki Mark W | Officer | SELL | $8.18 | 1,341 | $10,969 | 102,356 |
| 2026-03-26 00:00 | 2026-03-23 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | OPT+S | $8.18 | 2,894 | $23,673 | 1,051,607 |
| 2026-03-26 00:01 | 2026-03-23 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | SELL | $8.18 | 1,094 | $8,949 | 279,277 |
| 2026-03-25 23:23 | 2026-03-24 | PTGX | Protagonist Therapeutics, Inc | PATEL DINESH V PH D | Director, Officer | OPT+S | $101.00 | 54,700 | $5,524,700 | 524,938 |
| 2026-03-25 21:32 | 2026-03-24 | TPST | Tempest Therapeutics, Inc. | Angel Matthew | Director, Officer, 10% owner | BUY | $2.16 | 231,482 | $500,001 | 231,482 |
| 2026-03-25 21:05 | 2026-03-23 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $45.53 | 34,791 | $1,583,989 | 43,886 |
| 2026-03-25 20:30 | 2025-04-14 | PYXS | Pyxis Oncology, Inc. | HUMPHREY RACHEL | Director | SELL | $1.03 | 15,496 | $15,917 | 81,309 |
| 2026-03-25 20:30 | 2026-03-23 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $36.79 | 18,314 | $673,752 | 187,640 |
| 2026-03-25 20:31 | 2026-03-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $529.36 | 9,500 | $5,028,919 | 40,513 |
| 2026-03-25 15:13 | 2026-03-23 | LGND | LIGAND PHARMACEUTICALS INC | Sabba Stephen L | Director | SELL | $207.87 | 1,000 | $207,873 | 32,793 |
| 2026-03-24 20:19 | 2026-03-20 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $33.69 | 9,293 | $313,038 | 19,543 |
| 2026-03-24 20:05 | 2026-03-24 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $72.00 | 39,665 | $2,855,880 | 15,000 |
| 2026-03-25 01:15 | 2026-03-20 | RNXT | RenovoRx, Inc. | VOLL MARK | Officer | BUY | $0.00 | 97,200 | $0 | 97,200 |
| 2026-03-25 01:16 | 2026-03-20 | RNXT | RenovoRx, Inc. | Bagai Shaun | Director, Officer | BUY | $0.00 | 24,300 | $0 | 313,357 |
| 2026-03-25 01:16 | 2026-03-20 | RNXT | RenovoRx, Inc. | Marton Laurence | Director | BUY | $0.00 | 9,720 | $0 | 9,720 |
| 2026-03-24 23:45 | 2026-03-23 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.52 | 9,200 | $170,348 | 145,355 |
| 2026-03-24 23:24 | 2026-03-23 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.86 | 6,500 | $18,568 | 0 |
| 2026-03-24 22:56 | 2026-03-23 | OKUR | OnKure Therapeutics, Inc. | Leverone Jason A. | Officer | SELL | $4.16 | 301 | $1,251 | 16,000 |
| 2026-03-24 22:57 | 2026-03-23 | OKUR | OnKure Therapeutics, Inc. | Saccomano Nicholas A | Director, Officer | SELL | $4.16 | 86 | $357 | 7,333 |
| 2026-03-24 22:04 | 2026-03-23 | VTRS | Viatris Inc | Campbell Paul | Officer | SELL | $13.28 | 21,350 | $283,539 | 366,288 |
| 2026-03-24 20:54 | 2026-03-20 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | OPT+S | $36.01 | 11,767 | $423,730 | 2,231 |
| 2026-03-24 20:31 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | Olian Judy D. | Director | SELL | $530.00 | 200 | $106,000 | 4,245 |
| 2026-03-24 20:32 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $527.01 | 9,500 | $5,006,558 | 40,513 |
| 2026-03-24 20:33 | 2026-03-23 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $527.48 | 10,000 | $5,274,802 | 18,876 |
| 2026-03-23 20:05 | 2026-03-19 | ALXO | ALX ONCOLOGY HOLDINGS INC | Pinto Shelly | Officer | SELL | $2.17 | 903 | $1,960 | 86,805 |
| 2026-03-23 20:05 | 2026-03-19 | ALXO | ALX ONCOLOGY HOLDINGS INC | Lettmann Jason | Director, Officer | SELL | $2.17 | 12,311 | $26,715 | 293,609 |
| 2026-03-24 01:23 | 2026-03-20 | IMNM | Immunome Inc. | WAGENHEIM PHILIP | Director | SELL | $20.55 | 65,000 | $1,335,627 | 341,147 |
| 2026-03-23 23:36 | 2026-03-19 | IONS | IONIS PHARMACEUTICALS INC | Schneider Eugene | Officer | SELL | $70.97 | 5,812 | $412,486 | 63,890 |
| 2026-03-23 20:30 | 2026-03-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $524.99 | 9,500 | $4,987,387 | 40,513 |
| 2026-03-23 11:30 | 2026-03-19 | IBIO | iBio, Inc. | Brenner Martin | Director, Officer | BUY | $2.02 | 12,336 | $24,919 | 30,652 |
| 2026-03-23 11:31 | 2026-03-19 | IBIO | iBio, Inc. | Duran Felipe | Officer | BUY | $2.02 | 24,835 | $50,132 | 35,974 |
| 2026-03-20 20:05 | 2026-03-18 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer | OPT+S | $117.99 | 4,302 | $507,611 | 0 |
| 2026-03-20 20:25 | 2026-03-20 | OPK | OPKO HEALTH, INC. | PAGANELLI JOHN A | Director | BUY | $1.14 | 10,000 | $11,350 | 394,340 |
| 2026-03-20 20:05 | 2026-03-19 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $143.52 | 10,699 | $1,535,542 | 301,185 |
| 2026-03-20 23:19 | 2026-03-20 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $4.75 | 13,669 | $64,929 | 604,700 |
| 2026-03-20 23:19 | 2026-03-20 | EOLS | Evolus, Inc. | Avelar Rui | Officer | SELL | $4.75 | 3,119 | $14,815 | 427,423 |
| 2026-03-20 21:14 | 2026-03-18 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dieter David | Officer | SELL | $34.92 | 13,976 | $488,099 | 77,071 |
| 2026-03-20 21:02 | 2026-03-18 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $18.82 | 15,000 | $282,366 | 339,392 |
| 2026-03-20 20:30 | 2026-03-19 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $528.83 | 9,500 | $5,023,884 | 40,513 |
| 2026-03-20 20:17 | 2026-03-19 | ALDX | Aldeyra Therapeutics, Inc. | DOUGLAS RICHARD | Director | BUY | $1.40 | 70,000 | $98,000 | 195,000 |
| 2026-03-20 18:20 | 2026-03-19 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $2.50 | 39,000 | $97,500 | 0 |
| 2026-03-19 20:05 | 2026-03-17 | ZLAB | Zai Lab Ltd | GAYNOR RICHARD | Director | BUY | $18.91 | 1,731 | $32,733 | 56,630 |
| 2026-03-19 23:58 | 2026-03-17 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $52.40 | 22,880 | $1,198,818 | 73,320 |
| 2026-03-20 00:01 | 2026-03-18 | ARVN | ARVINAS, INC. | Berkowitz Noah | Officer | SELL | $11.10 | 6,435 | $71,431 | 202,503 |
| 2026-03-19 22:35 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | McCarthy Sean A. | Director, Officer | SELL | $6.42 | 118,969 | $764,138 | 1,078,922 |
| 2026-03-19 22:36 | 2026-03-17 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $28.24 | 200,000 | $5,648,000 | 1,647,546 |
| 2026-03-19 22:41 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | Chu Yu-Waye | Officer | SELL | $6.42 | 21,279 | $136,675 | 189,446 |
| 2026-03-19 22:21 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | Officer | SELL | $6.42 | 19,323 | $124,112 | 296,948 |
| 2026-03-19 22:25 | 2026-03-17 | CTMX | CytomX Therapeutics, Inc. | BELVIN MARCIA | Officer | SELL | $6.42 | 31,492 | $202,273 | 300,760 |
| 2026-03-19 21:50 | 2026-03-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer | OPT+S | $27.76 | 5,000 | $138,800 | 25,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.